Pharma & biotech
Volitionrx Ltd (NYSE:VNRX), a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced interim results from a 680-subject clinical trial in colorectal cancer. The study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer using Volition’s Nu.Q™ blood test.